Esophageal Diseases  >>  TheraCIM (nimotuzumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
NCT00950417: Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer

Completed
1
11
RoW
Nimotuzumab
Biotech Pharmaceutical Co., Ltd.
Advanced Esophageal
07/10
11/12

Download Options